Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. Inhibitors of the mammalian target of rapamycin are a new class of immunosuppressants. There are three commercially available mammalian (mechanistic) target of rapamycin (mTOR) inhibitors approved by the U.S. Food and Drug Administration (FDA) approved: sirolimus, everolimus, and temsirolimus. Mammalian target of rapamycin (mTOR) inhibitors are used in the treatment of renal cancer and is being studied for use in other types of cancers. Mechanistic target of rapamycin (mTOR) inhibitors provides more benefits when used with chemotherapy agents to treat cancers.
Global mTOR Inhibitors Market - Impact of the Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has negatively impacted the growth of global mTOR inhibitors market. The COVID-19 pandemic affected the health care systems globally and resulted in the interruption of usual care in many health care facilities, exposing vulnerable patients with cancer to significant risks. Our study aimed to evaluate the impact of this pandemic on cancer care worldwide. According to an article published by American Society of Clinical Oncology, in September 2020, a survey was conducted by An American Society of Clinical Oncology Journal, total of 356 centers from 54 countries across six continents participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer a year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%). Participants reported patient exposure to harm from interruption of cancer-specific care (36.52%) and non-cancer-related care (39.04%), with some centers estimating that up to 80% of their patients were exposed to harm. Thus, the COVID-19 has negatively impacted the global mTOR inhibitors market.
Global mTOR inhibitors market is estimated to be valued at US$ 6,704.5 thousand in 2022 and expected to exhibit a CAGR of 4.5% over the forecast period (2022-2030).
Figure 1: Global mTOR Inhibitors Market Share (%) Analysis, By Drug Type, 2022
The increasing number of generic drug launches by the market players is expected to drive the growth of global mTOR inhibitors market over the forecast period.
Market players are focused on organic growth strategies such as drug launches, which is expected to drive the market growth over the forecast period. For instance, in February 2018, Biocon Ltd., a biopharmaceutical company announced the launch of Everolimus tablets, a generic version of Afinitor, in the U.S. Everolimus tablets will be introduced in 2.5mg, 5mg, 7.5mg and 10mg strengths.
mTOR Inhibitors Market Report Coverage
|Base Year:||2019||Market Size in 2022:||US$ 6,704.5 Mn|
|Historical Data for:||2016 to 2019||Forecast Period:||2022 to 2030|
|Forecast Period 2020 to 2027 CAGR:||4.5%||2030 Value Projection:||US$ 9,534.5 Mn|
Novartis AG, Hikma Pharmaceuticals PLC., Par Pharmaceutical, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Cadilla, Pfizer, Inc., Biocon, Alkem Laboratories Ltd., Accord Healthcare Inc., Gland Pharma Ltd., Apotex Inc., and Glenmark Pharmaceuticals Ltd.
|Restraints & Challenges:||
The increasing number of product approvals from regulatory bodies is expected to drive the growth of global mTOR inhibitors market over the forecast period.
Market players are focused on gaining product approvals from regulatory bodies, which is expected to drive the growth of global mTOR inhibitors market over the forecast period. For instance, in October 2020, Glenmark Pharmaceuticals, a pharmaceutical company, announced that the U.S. Food and Drug Administration has approved generic version of Rapamune tablets, 0.5mg, 1mg and 2mg. The drug is the generic version of Pfizer, Inc. and Wyeth Pharmaceuticals, a pharmaceutical company’s Rapamune tablets.
Global mTOR Inhibitors Market – Restraints
The high price of drugs (including branded and generic) is a major hurdle for the market growth. For instance, according to Drugs. Com., the price of Temsirolimus intravenous solution (25mg/mL), indicated for the treatment of advanced renal cell carcinoma is around US$ 1,213.
Global mTOR Inhibitors Market – Region Analysis
On the basis of region, global mTOR inhibitors market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa.
North America is expected to hold a dominant position in the market during the forecast period, owing to increasing number of product approvals from regulatory bodies in the region. For instance, in February 2016, Novartis AG, a pharmaceutical company, announced that the U.S.Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.
Figure 2: Global mTOR Inhibitors Market (US$ Mn), by Country, 2022
Global mTOR Inhibitors Market – Competitive Landscape
Major players operating in global mTOR inhibitors market include Novartis AG, Hikma Pharmaceuticals PLC., Par Pharmaceutical, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Cadilla, Pfizer, Inc., Biocon, Alkem Laboratories Ltd., Accord Healthcare Inc., Gland Pharma Ltd., Apotex Inc., and Glenmark Pharmaceuticals Ltd.
Frequently Asked Questions